Anti-Diabetes Drug Pioglitazone Ameliorates Synaptic Defects in AD Transgenic Mice by Inhibiting Cyclin-Dependent Kinase5 Activity

Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons

(2013) Du-Hyong Cho et al.   JOURNAL OF NEUROCHEMISTRY

Intranasal administration of nerve growth factor ameliorate β-amyloid deposition after traumatic brain injury in rats

(2012) Lili Tian et al.   BRAIN RESEARCH

A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice

(2012) Varsha Shukla et al.   FASEB JOURNAL

PPARγagonist pioglitazone improves scopolamine-induced memory impairment in mice

(2012) Guo Qing Xiang et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease

(2012) Rachna Gupta et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

S-nitrosylation of Cdk5

(2012) Jing Qu et al.   Prion

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD and wild-type mice

(2012) F Masciopinto et al.   Cell Death & Disease

Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk

(2012) Giuseppe Derosa et al.   Current Molecular Pharmacology

Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease

(2011) Benjamin W Miller et al.   ANNALS OF PHARMACOTHERAPY

Cyclin-Dependent Kinases in Brain Development and Disease

(2011) Susan C. Su et al.   Annual Review of Cell and Developmental Biology

Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease

(2011) Alan S. L. Wong et al.   NATURE CELL BIOLOGY

S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by  -amyloid peptide

(2011) J. Qu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cdk5: a multifaceted kinase in neurodegenerative diseases

(2011) Zelda H. Cheung et al.   TRENDS IN CELL BIOLOGY

A 24-Residue Peptide (p5), Derived from p35, the Cdk5 Neuronal Activator, Specifically Inhibits Cdk5-p25 Hyperactivity and Tau Hyperphosphorylation

(2010) Ya-Li Zheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5

(2010) Jang Hyun Choi et al.   NATURE

Early Alzheimer's Disease

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models

(2010) Bénédicte Menn et al.   PLoS One

Recent advances in understanding the roles of Cdk5 in synaptic plasticity

(2009) Kwok-On Lai et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD

(2009) Masashi Kitazawa et al.   JOURNAL OF NEUROCHEMISTRY

c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice

(2009) Gonzalo I. Cancino et al.   NEUROBIOLOGY OF AGING

The atypical kinase Cdk5 is activated by insulin, regulates the association between GLUT4 and E-Syt1, and modulates glucose transport in 3T3-L1 adipocytes

(2009) V. Lalioti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease

(2008) Wei-Qin Zhao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Peroxisome Proliferator-Activated Receptor   Pathway Targeting in Carcinogenesis: Implications for Chemoprevention

(2008) F. Ondrey   CLINICAL CANCER RESEARCH